Positive impactIPO

Tata Sons likely to list, Tata Chemicals could be biggest beneficiary, says Deven Choksey

CNBC-TV18 1 hr ago·18 Sept 2026, 5:16 am

Deven Choksey of DRChoksey Finserv has highlighted Tata Chemicals as a potential top beneficiary if the parent company, Tata Sons, proceeds with its much-anticipated initial public offering (IPO). The analyst believes a listing of the holding company could unlock significant value for its key subsidiaries, with Tata Chemicals being a primary target.

For investors, this development suggests a potential catalyst for the stock, as a stronger parent entity often enhances the financial health and valuation of its operating units. The move aligns with the broader trend of large conglomerates seeking to unlock value for shareholders through partial listings.

What to watch next is the timeline for any official announcements regarding the IPO. Investors should also monitor the valuation multiples applied to the parent company, as these will directly influence the expected upside for its listed subsidiaries.

Excerpt from CNBC-TV18

Deven Choksey of DRChoksey Finserv expects Tata Sons to list eventually, naming Tata Chemicals as the top beneficiary. He also backs the NSE IPO for its profit distribution and calls large-cap valuations compelling right now. Disclaimer: The views and tips expressed by investment experts on CNBCTV18.com are their own,…
Read the original at CNBC-TV18

Affected stocks

Bullish1 stock

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

  • Concerns Tata Chemicals (TATACHEM).
  • Category: IPO.
  • AI reads the tone as positive (potentially bullish) for the stock.
  • Assessed as a significant, market-relevant update.

Why it matters

A meaningful update for Tata Chemicals worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at CNBC-TV18.

More IPO news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.